These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 3519263)

  • 41. Correlation of hematologic recovery with CFU-GM content of autologous bone marrow grafts treated with 4-hydroperoxycyclophosphamide. Culture after cryopreservation.
    Rowley SD; Piantadosi S; Santos GW
    Bone Marrow Transplant; 1989 Sep; 4(5):553-8. PubMed ID: 2790333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
    Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
    Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow.
    Beaujean F; Hartmann O; Benhamou E; Lemerle J; Duedari N
    Bone Marrow Transplant; 1989 Sep; 4(5):537-41. PubMed ID: 2790332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma: comparison of different parameters in predicting the kinetics of haematological recovery.
    Visani G; Dinota A; Verlicchi F; Bandini G; Ricci P; Motta MR; Rizzi S; Lemoli RM; Poluzzi C; Gherlinzoni F
    Bone Marrow Transplant; 1988 Nov; 3(6):599-605. PubMed ID: 2905614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation.
    Mitsuyasu RT; Li SN; Champlin RE; Gale RP
    Exp Hematol; 1986 Dec; 14(11):1049-55. PubMed ID: 3536545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of rhG-CSF scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice.
    Scheding S; Media JE; Nakeff A
    Stem Cells; 1998; 16(2):144-51. PubMed ID: 9554039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of factors affecting hematopoietic recovery after autologous bone marrow transplantation for lymphoma.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Nov; 6(5):291-4. PubMed ID: 2291991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An unusual pattern of hemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood.
    To LB; Haylock DN; Dyson PG; Thorp D; Roberts MM; Juttner CA
    Bone Marrow Transplant; 1990 Aug; 6(2):109-14. PubMed ID: 1976398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Recovery of hematopoiesis after high-dose chemotherapy and peripheral blood stem cell autografts in children].
    Sato J; Takaue Y; Okamoto Y; Saito S; Hirao A; Matsunaga K; Shimizu T; Abe T; Watanabe T; Kawano Y
    Rinsho Ketsueki; 1992 May; 33(5):637-45. PubMed ID: 1352832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation.
    Stoppa AM; Blaise D; Viens P; Baume D; Mannoni P; Novakovitch G; David FA; Yver A; Maraninchi D
    Bone Marrow Transplant; 1994 May; 13(5):541-7. PubMed ID: 7519936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stem cells from peripheral blood and bone marrow: a comparative evaluation of the hemopoietic potential in the dog.
    Raghavachar A; Prümmer O; Fliedner TM; Calvo W; Steinbach IB
    Int J Cell Cloning; 1983 Sep; 1(4):191-205. PubMed ID: 6366082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
    Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
    Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.
    Millar BC; Millar JL; Shepherd V; Blackwell P; Porter H; Cunningham D; Judson I; Treleaven J; Powles RL; Catovsky D
    Bone Marrow Transplant; 1998 Sep; 22(5):469-75. PubMed ID: 9733270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.